




# PHARMACEUTICAL 2023

## PROVECTUS BIOPHARMACEUTICALS INC. Rank 408 of 446





# PHARMACEUTICAL 2023

## PROVECTUS BIOPHARMACEUTICALS INC. Rank 408 of 446

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 9.7% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -277%, being 320% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,899
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,192
Liabilities, Non-Current	73
Other Assets	117
Other Compr. Net Income	-1.2
Other Expenses	0
Other Liabilities	0
Other Net Income	-127
Other Revenues	989
Property and Equipment	21
Research and Development	2,389
Selling, General and Administrative Expense	2,028

Output Variable	Value in 1000 USD
Assets	2,037
Liabilities	8,266
Expenses	4,417
Revenues	989
Stockholders Equity	-6,229
Net Income	-3,555
Comprehensive Net Income	-3,555
Economic Capital Ratio	-277%